Measles Mumps and Rubella (MMR) Vaccines Market Opportunity Analysis, 2018 – 2026

13 Likes Comment

Vaccine manufacturers are focusing on partnering with organizations such WHO, UNICEF, and GAVI Alliance to improve their vaccination programs, in order to reach the maximum population to offer vaccines.

Measles, mumps, and rubella are the three common contagious airborne diseases that are highly caused by virus transmitted by sneezing and coughing of the infected person, which could lead to serious complications or death among children. Vaccines of these diseases are sold as attenuated viral vaccines, manufactured in a lyophilised formulation, which requires reconstitution with water for injection diluent and are available in two forms i.e. monovalent as well as combinational vaccines. Combinational MMR vaccines comprises mixture of two or more viral strains.

These measles, mumps, and rubella vaccines are administered by subcutaneous injection to children as well as adults. It is generally administered to children aged 1 year and second dosage can be administered as early as one month after the first dose. According to CDC, two doses of measles, mumps and rubella vaccine are 97% effective against measles and 88% effective against mumps. One dose of measles, mumps, and rubella vaccine is 93% effective against measles, 78% effective against mumps, and 97% effective against rubella.

Currently, few vaccines available in the measles, mumps, and rubella vaccine market are sold under the trade name of M-M-R II, ProQuad, and Attenuvax by Merck Co. Inc.; Varilrix, Priorixtetra and MMR by GSK; Trimovax by Sanofi Pasteur and Tresivac by Serum Institute of India.

In spite of several governmental initiatives, measles is a leading cause of death among young children. Therefore, increasing success rate of vaccination programmes depends on government initiatives of each country. Some organizations are focusing on initiative, in order to reduce the prevalence of these diseases. For instance, GAVI Alliances has undertaken an initiative to provide vaccination in high-risk countries such as Afghanistan, Chad, Ethiopia, the Democratic Republic of the Congo, Nigeria and Pakistan. Similarly, in 2017, the Government of India launches Pan-India Measles-Rubella vaccination campaign, under which children ages from 9 months to 15 years are vaccinated to reduce the incidence of these disease in children. Such initiatives by various organizations and governments is expected to aid in growth of the market. Furthermore, development of combinational vaccines could aid in reducing cost and adverse effects by reducing the number of vaccination programme.

Key Vendors:

GlaxoSmithKline (Belgium), Merck & Co. Inc. (USA) and Serum Institute of India Ltd, among others.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
SeattleFind Article, WA 98154
Tel: +1-206-701-6702

You might like

About the Author: Tenali Rama

elani Rama Rivera is a 28-year-old trainee tradesperson who enjoys running, cycling and helping old ladies across the road. He is creative and considerate, but can also be very lazy and a bit dull. He is Pakistan. He started college but never finished the course. Physically, Telani is in pretty good shape. He is average-height with brown skin, brown hair and black eyes. He grew up in a middle class neighbourhood. He was raised in a happy family home with two loving parents. He is currently married to Lacey Abbie Griffin. Lacey is the same age as him and works as a cleaner. Telani has one child with wife Lacey: Meghan aged 2. Telani's best friend is a trainee tradesperson called Francis Clark. They have a very firey friendship. He also hangs around with Norman Davies and Hannah Price. They enjoy social media together.

Leave a Reply

Your email address will not be published. Required fields are marked *